GTC
APLS

Ghost Tree Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Ghost Tree Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-300,000
Closed -$9.19M – 51
2019
Q4 		$9.19M Buy
+300,000
New +$8.3M 1.75% 21

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ghost Tree Capital's APLS Position: Q3 2024 in Review

Ghost Tree Capital reduced its Apellis Pharmaceuticals (APLS) stake by 52% in Q3 2024, selling an estimated $2.59M and leaving 65,000 shares worth $1.87M. The position accounts for 0.57% of the portfolio, ranked #46.

Ghost Tree Capital first reported a position in APLS in Q2 2018 and has held it in 16 quarters since. The position peaked at $18.8M in Q3 2022. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • Ghost Tree Capital held 65,000 shares of Apellis Pharmaceuticals worth $1.87M as of Q3 2024.
  • Ghost Tree Capital sold 70,000 Apellis Pharmaceuticals shares in Q3 2024, an estimated $2.59M.
  • Apellis Pharmaceuticals made up 0.57% of Ghost Tree Capital's portfolio in Q3 2024, its #46 holding.
  • Ghost Tree Capital first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 16 quarters since.
  • Ghost Tree Capital's Apellis Pharmaceuticals position peaked at $18.8M in Q3 2022.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.